首页> 外文期刊>Journal of public health policy >Drug information, misinformation, and disinformation on social media: a content analysis study.
【24h】

Drug information, misinformation, and disinformation on social media: a content analysis study.

机译:在社交媒体上的药物信息,错误信息和虚假信息:内容分析研究。

获取原文
获取原文并翻译 | 示例
           

摘要

Dissemination of misleading drug information through social media can be detrimental to the health of the public. This study, carried out in Bahrain, evaluated the truthfulness爋f 22 social media claims about drugs (72.7%), dietary supplements (22.7%), and toxic bisphenol-A (4.5%). They circulated on WhatsApp platform, as case studies. We categorized claims as objectively true, false, or potentially misleading. The content analysis revealed that "potentially misleading" claims were the most frequent messages (59.1%). They tend to exaggerate the efficacy or safety without sufficient evidence to substantiate claims. False claims (27.3%) were likely due to unfair competition or deception. Overall, 13.6% of the messages were objectively true claims that could withstand regulatory scrutiny. Majority of the drug-related messages on social media were potentially misleading or false claims that lacked credible evidence to support them. In the public interest, regulatory authorities should monitor such information disseminated via social media platforms.
机译:通过社交媒体传播误导药物信息可能对公众的健康有害。在巴林进行的这项研究评估了真实性爋F22社交媒体索赔的药物(72.7%),膳食补充剂(22.7%)和有毒双酚-A(4.5%)。他们在WhatsApp平台上分发,如案例研究。我们将索赔分类为客观真实,假或潜在的误导。内容分析显示“潜在误导性”声明是最常见的消息(59.1%)。他们倾向于夸大效果或安全,而没有充分证据证实权利要求。由于不公平的竞争或欺骗,可能是由于不公平的竞争或欺骗性的错误索赔(27.3%)。总体而言,13.6%的消息是客观的真正索赔,可以承受监管审查。关于社交媒体的大多数毒品相关信息都是潜在的误导性或虚假声明,缺乏可靠的证据来支持它们。在公共利益中,监管机构应监测通过社交媒体平台传播的此类信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号